---
title: "NewcelX appoints diabetes researcher Camillo Ricordi to scientific advisory board"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292074630.md"
description: "NewcelX has appointed diabetes researcher Camillo Ricordi to its Scientific Advisory Board. Ricordi, a prominent figure in cellular transplantation and beta-cell replacement from the University of Miami, will advise on the clinical translation of NewcelX's biologic replacement strategy for Type 1 diabetes. He will also support collaborations with Eledon Pharmaceuticals."
datetime: "2026-07-08T13:15:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292074630.md)
  - [en](https://longbridge.com/en/news/292074630.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292074630.md)
generator: "portal-rs"
---

# NewcelX appoints diabetes researcher Camillo Ricordi to scientific advisory board

-   NewcelX appointed Camillo Ricordi to its Scientific Advisory Board as it advances its Type 1 diabetes cell-therapy program. \* Ricordi is chief of the Division of Cellular Transplantation at the University of Miami Miller School of Medicine. \* He is director of the Cell Transplant and NABTU Regenerative Medicine Center, director emeritus of the Diabetes Research Institute. \* NewcelX highlighted his work in beta-cell replacement, islet transplantation, 1,250 publications, 64,000 citations, h-index 123. \* Ricordi will advise clinical translation of the company’s biologic replacement strategy, support collaboration with Eledon Pharmaceuticals. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607080915PRIMZONEFULLFEED9758526) on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [NCEL.US](https://longbridge.com/en/quote/NCEL.US.md)
- [ELDN.US](https://longbridge.com/en/quote/ELDN.US.md)
- [NLSP.US](https://longbridge.com/en/quote/NLSP.US.md)
- [NLSPW.US](https://longbridge.com/en/quote/NLSPW.US.md)

## Related News & Research

- [NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes | NCEL Stock News](https://longbridge.com/en/news/287766589.md)
- [Biomea Fusion completes enrollment in COVALENT-211 Phase II icovamenib trial in insulin-deficient type 2 diabetes](https://longbridge.com/en/news/296776922.md)
- [Quest Diagnostics teams with Humanity to offer biological age analysis on Questhealth.com](https://longbridge.com/en/news/296926398.md)
- [Lexaria says DehydraTECH 3.0 retatrutide tablet boosts absorption up to 4,552% in dog study](https://longbridge.com/en/news/296793626.md)
- [374Water completes Phase 3 of St. Cloud mobile AirSCWO deployment for PFAS-laden biosolids](https://longbridge.com/en/news/296910774.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**